Cholesterol paradox: Is high total or low HDL cholesterol level a risk for Alzheimer's disease?

Journal of Neuroscience Research

Volumn 72, Issue 2, 2003, Pages 141-146

  Michikawa, Makoto ^a  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Alzheimer's disease; Amyloid protein; Amyloid cascade; Apolipoprotein E; Cholesterol; HDL; Statin

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALLELE; ALZHEIMER DISEASE; CELL LEVEL; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID LEVEL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; COGNITIVE DEFECT; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; HUMAN; NERVE CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; TAUOPATHY;

ALZHEIMER DISEASE; AMYLOID; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS E; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HUMANS; HYPERCHOLESTEROLEMIA; RISK FACTORS; TAU PROTEINS;

EID: 0037445920     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.10585     Document Type: Short Survey

References (59)

1. Auer IA, Schmidt ML, Lee VM, Curry B, Suzuki K, Shin RW, Pentchev PG, Carstea ED, Trojanowski JQ. 1995. Paired helical filament tau (PHFtau) in Niemann-Pick type C disease is similar to PHFtau in Alzheimer's disease. Acta Neuropathol (Berl) 90:547-551.
2. Borghini I, Barja F, Pometta D, James RW. 1995. Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochim Biophys Acta 1255:192-200.
3. Bouthillier D, Sing CF, Davignon J. 1983. Apolipoprotein E phenotyping with a single gel method: application to the study of informative matings. J Lipid Res 24:1060-1069.
4. Braeckman L, De Bacquer D, Rosseneu M, De Backer G. 1996. Apolipoprotein E polymorphism in middle-aged Belgian men: phenotype distribution and relation to serum lipids and lipoproteins. Atherosclerosis 120:67-73.
5. Chong PH, Kezele R, Franklin C. 2002. High-density lipoprotein cholesterol and the role of statins. Circ J 66:1037-1044.
6. Craig AM, Banker G. 1994. Neuronal polarity. Annu Rev Neurosci 17:267-310.
7. Davignon J, Gregg RE, Sing CF. 1988. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8:1-21.
8. Distl R, Meske V, Ohm TG. 2001. Tangle-bearing neurons contain more free cholesterol than adjacent tangle-free neurons. Acta Neuropathol (Berl) 101:547-554.
9. Eckert GP, Kirsch C, Muller WE, 2001. Differential effects of lovastatin treatment on brain cholesterol levels in normal and ApoE-deficient mice. Neuroreport 12:883-887.
10. Evans RM, Emsley CL, Gao S, Sahota A, Hall KS, Farlow MR, Hendrie H. 2000. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 54: 240-242.
11. Fagan AM, Younkin LH, Morris JC, Fryer JD, Cole TG, Younkin SG, Holtzman DM, 2000. Differences in the Aβ40/Aβ42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann Neurol 48:201-210.
12. Fan QW, Isobe I, Asou H, Yanagisawa K, Michikawa M. 2001a. Expression and regulation of apolipoprotein E receptors in the cells of the central nervous system in culture: A review. J Am Aging Assoc 24:1-10.
13. Fan QW, Wei Y, Senda T, Yanagisawa K, Michikawa M. 2001b. Cholesterol-dependent modulation of tau phosphorylation in cultured neurons. J Neurochem 76:391-400.
14. Fan QW, Yu W, Gong JS, Zou K, Sawamura N, Senda T, Yanagisawa K, Michikawa M. 2002. Cholesterol-dependent modulation of dendrite outgrowth and microtubule stability in cultured neurons. J Neurochem 80:178-190.
15. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T. 2001. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci USA 98:5856-5861.
16. Fassbender K, Stroick M, Bertsch T, Ragoschke A, Kuehl S, Walter S, Walter J, Brechtel K, Muehlhauser F, Von Bergmann K, Lutjohann D. 2002. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 59:1257-1258.
17. Frikke-Schmidt R, Nordestgaard BG, Agerholm-Larsen B, Schnohr P, Tybjaerg-Hansen A. 2000. Context-dependent and invariant associations between lipids, lipoproteins, and apolipoproteins and apolipoprotein E genotype. J Lipid Res 41:1812-1822.
18. Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, Cho M, Musliner TA, Gumbiner B. 2002. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 90:1084-1091.
19. Gong JS, Kobayashi M, Hayashi H, Zou K, Sawamura N, Fujita SC, Yanagisawa K, Michikawa M. 2002b. Apolipoprotein E (apoE)-isoformdependent lipid release from astrocytes prepared from human-apoE3- and apoE4-knock-in mice. J Biol Chem 277:29919-29926.
20. Gong JS, Sawamura N, Zou K, Sakai J, Yanagisawa K, Michikawa M. 2002a. Amyloid β-protein affects cholesterol metabolism in cultured neurons: implications for pivotal role of cholesterol in the amyloid cascade. J Neurosci Res 70:438-446.
21. Hess DC, Demchuk AM, Brass LM, Yatsu FM. 2000. HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention. Neurology 54:790-796.
22. Hoshino T, Kamino K, Matsumoto M. 2002. Gene dose effect of the APOE-epsilon4 allele on plasma HDL cholesterol level in patients with Alzheimer's disease. Neurobiol Aging 23:41-45.
23. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB. 1995. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 45:1092-1096.
24. Jurevics H, Hostettler J, Barrett C, Morell P, Toews AD. 2000. Diurnal and dietary-induced changes in cholesterol synthesis correlate with levels of mRNA for HMG-CoA reductase. J Lipid Res 41:1048-1054.
25. Kakio A, Nishimoto SI, Yanagisawa K, Kozutsumi Y, Matsuzaki K. 2001. Cholesterol-dependent formation of GM1 ganglioside-bound amyloid β-protein, an endogenous seed for Alzheimer amyloid. J Biol Chem 276:24985-24990.
26. Kakio A, Nishimoto S, Yanagisawa K, Kozutsumi Y, Matsuzaki K. 2002. Interactions of amyloid β-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 41:7385-7390.
27. Kivipelto M, Helkala EL, Hanninen T, Laakso MP, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A. 2001. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 56:1683-1989.
28. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F. 2001. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc Natl Acad Sci USA 98:5815-5820.
29. Koudinov AR, Koudinova NV. 2001. Essential role for cholesterol in synaptic plasticity and neuronal degeneration. FASEB J 15:1858-1860.
30. Launer LJ, White LR, Petrovitch H, Ross GW, Curb JD. 2001. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology 57:1447-1452.
31. Lehtinen S, Lehtimaki T, Sisto T, Salenius JP, Nikkila M, Jokela H, Koivula T, Ebeling F, Ehnholm C. 1995. Apolipoprotein E polymorphism, serum lipids, myocardial infarction and severity of angiographically verified coronary artery disease in men and women. Atherosclerosis 114:83-91.
32. Liu Y, Peterson DA, Schubert D. 1998. Amyloid β-peptide alters intracellular vesicle trafficking and cholesterol homeostasis. Proc Natl Acad Sci USA 95:13266-13271.
33. Love S, Bridges LR, Case CP. 1995. Neurofibrillary tangles in NiemannPick disease type C. Brain 118:119-129.
34. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, Pfrieger FW. 2001. CNS synaptogenesis promoted by glia-derived cholesterol. Science 294:1354-1357.
35. Merched A, Xia Y, Visvikis S, Serot JM, Siest G. 2000. Decreased highdensity lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol Aging 21:27-30.
36. Michikawa M, Yanagisawa K. 1999. Inhibition of cholesterol production but not of nonsterol isoprenoid products reduces neuronal cell death. J Neurochem 72:2278-2285.
37. Michikawa M, Fan QW, Isobe I, Yanagisawa K. 2000. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem 74:1008-1016.
38. Michikawa M, Gong JS, Fan QW, Sawamura N, Yanagisawa K. 2001. A novel action of Alzheimer's amyloid β-protein (Aβ): oligomeric Aβ promotes lipid release. J Neurosci 21:7226-7235.
39. Mulder M, Ravid R, Swaab DF, de Kloet ER, Haasdijk ED, Julk J, van der Boom JJ, Havekes LM. 1998. Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4. Alzheimer Dis Assoc Disord 12: 198-203.
40. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, Tuomilehto J, Nissinen A. 1998. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 17:14-20.
41. Okabe S, Kim HD, Miwa A, Kuriu T, Okado H. 1999. Continual remodeling of postsynaptic density and its regulation by synaptic activity. Nat Neurosci 2:804-811.
42. Petanceska SS, DeRosa S, Olm V, Diaz N, Sharma A, Thomas-Bryant T, Duff K, Pappolla M, Refolo LM. 2002. Statin therapy for Alzheimer's disease: will it work? J Mol Neurosci 19:155-161.
43. Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW. 1987a. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta 917:148-161.
44. Pitas BE, Boyles JK, Lee SH, Hui D, Weisgraber KH. 1987b. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J Biol Chem 262:14352-14360.
45. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA. 2000. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7:321-331.
46. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, ThomasBryant T, Tint GS, Wang R, Mercken M, Petanceska SS, Duff KE. 2001. A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8:890-899.
47. Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, Wolfson C, McDowell I. 2002. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59:223-227.
48. Roheim PS, Carey M, Forte T, Vega GL. 1979. Apolipoproteins in human cerebrospinal fluid. Proc Natl Acad Sci USA 76:4646-4649.
49. Roher AE, Weiss N, Kokjohn TA, Kuo YM, Kalback W, Anthony J, Watson D, Luehrs DC, Sue L, Walker D, Emmerling M, Goux W, Beach T. 2002. Increased Aβ peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry 41:11080-11090.
50. Sawamura N, Gong JS, Garver WS, Heidenreich RA, Ninomiya H, Ohno K, Yanagisawa K, Michikawa M. 2001. Site-specific phosphorylation of tau accompanied by activation of mitogen-activated protein kinase (MAPK) in brains of Niemann-Pick type C mice. J Biol Chem 276: 10314-10319.
51. Simons K, Ikonen E. 1997. Functional rafts in cell membranes. Nature 387:569-572.
52. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. 1998. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 95:6460-6464.
53. Sparks DL. 1996. Intraneuronal β-amyloid immunoreactivity in the CNS. Neurobiol Aging 17:291-299.
54. Sparks DL, Scheff SW, Hunsaker JC 3rd, Liu H, Landers T, Gross DR. 1994. Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126:88-94.
55. Suzuki K, Parker CC, Pentchev PG, Katz D, Ghetti B, D'Agostino AN, Carstea ED. 1995. Neurofibrillary tangles in Niemann-Pick disease type C. Acta Neuropathol (Berl) 89:227-238.
56. Wang YX, Martin-McNulty B, Huw LY, da Cunha V, Post J, Hinchman J, Vergona R, Sullivan ME, Dole W, Kauser K. 2002. Antiatherosclerotic effect of simvastatin depends on the presence of apolipoprotein E. Atherosclerosis 162:23-31.
57. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. 2000. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 57:1439-1443.
58. Yanagisawa K, Matsuzaki K. 2002. Cholesterol-dependent aggregation of amyloid β-protein. Ann N Y Acad Sci 977:384-386.
59. Yanagisawa K, Odaka A, Suzuki N, Ihara Y. 1995. GM1 gangliosidebound amyloid β-protein (Aβ): a possible form of pre-amyloid in Alzheimer's disease. Nat Med 1:1062-1066.